Applications of the partial-order continual reassessment method in the early development of treatment combinations
Authors:
- 30 March 2024
- journal article
- research article
- Published by SAGE Publications in Clinical Trials
- Vol. 21 (3) , 331-339
Abstract
Combination therapy is increasingly being explored as a promising approach for improving cancer treatment outcomes. However, identifying effective dose combinations in early oncology drug development is challenging due to limited sample sizes in early-phase clinical trials. This task becomes even more complex when multiple agents are being escalated simultaneously, potentially leading to a loss of monotonic toxicity order with respect to the dose. Traditional single-agent trial designs are insufficient for this multi-dimensional problem, necessitating the development and implementation of dose-finding methods specifically designed for drug combinations. While, in practice, approaches to this problem have focused on preselecting combinations with a known toxicity order and applying single-agent designs, this limits the number of combinations considered and may miss promising dose combinations. In recent years, several novel designs have been proposed for exploring partially ordered drug combination spaces with the goal of identifying a maximum tolerated dose combination, based on safety, or an optimal dose combination, based on toxicity and efficacy. However, their implementation in clinical practice remains limited. In this article, we describe the application of the partial order continual reassessment method and its extensions for combination therapies in early-phase clinical trials. We present completed trials that use safety endpoints to identify maximum tolerated dose combinations and adaptively use both safety and efficacy endpoints to determine optimal treatment strategies. We discuss the effectiveness of the partial-order continual reassessment method and its extensions in identifying optimal treatment strategies and provide our experience with executing these novel adaptive designs in practice. By utilizing innovative dose-finding methods, researchers and clinicians can more effectively navigate the challenges of combination therapy development, ultimately improving patient outcomes in the treatment of cancer.Keywords
Funding Information
- National Cancer Institute (R01CA247932)
This publication has 38 references indexed in Scilit:
- Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trialStatistics in Medicine, 2022
- A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trialsStatistics in Medicine, 2016
- Implementation of adaptive methods in early‐phase clinical trialsStatistics in Medicine, 2016
- A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sitesCancer Immunology, Immunotherapy, 2015
- A product of independent beta probabilities dose escalation design for dual‐agent phase I trialsStatistics in Medicine, 2015
- A Bayesian dose‐finding design for drug combination clinical trials based on the logistic modelPharmaceutical Statistics, 2014
- Phase I/II adaptive design for drug combination oncology trialsStatistics in Medicine, 2014
- Specifications of a continual reassessment method design for phase I trials of combined drugsPharmaceutical Statistics, 2013
- Calibration of prior variance in the Bayesian continual reassessment methodStatistics in Medicine, 2011
- A non‐parametric approach to the design and analysis of two‐dimensional dose‐finding trialsStatistics in Medicine, 2004